IL33 and chronic myelogenous leukemia, BCR-ABL1 positive: These data demonstrated that CML cells were sensitive to IL-33, which was capable of sustaining proliferation and cytokine production both directly, indirectly by the expression of ST2, and by controlling the neoplastic microenvironment, suggesting a new therapeutic approach.